Literature DB >> 11181793

Oxidized LDL suppresses NF-kappaB and overcomes protection from apoptosis in activated endothelial cells.

Kathrin Heermeier1, Wolfgang Leicht1, Alois Palmetshofer2, Markus Ullrich1, Christoph Wanner1, Jan Galle1.   

Abstract

Atherosclerosis is a chronic inflammatory disease associated with enhanced apoptotic cell death in vascular cells, partly induced by oxidized low-density lipoprotein (OxLDL). However, proinflammatory stimuli such as lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha) activate endothelial cells (EC) and inhibit apoptosis through induction of nuclear factor kappaB (NF-kappaB)-dependent genes. This study therefore investigated whether OxLDL or its component, lysophosphatidylcholine (LPC), interacts with the effect of LPS or TNF-alpha on cell survival. Human EC were incubated with LPS, TNF-alpha, OxLDL, or LPC alone or in combinations. OxLDL (100 to 200 microg/ml) and LPC (100 to 300 microM) induced apoptosis dose-dependently. LPS and TNF-alpha had no effect on cell survival in the presence or absence of OxLDL or LPC. LPS and TNF-alpha both induced the antiapoptotic gene A20, whereas OxLDL and LPC suppressed its induction. Expression of A20 is regulated by NF-kappaB. OxLDL and LPC dose-dependently suppressed NF-kappaB activity. For functional analysis, bovine EC were transfected with A20 encoding expression constructs in sense and antisense orientation. Bovine EC that overexpressed A20 were protected against OxLDL-induced apoptosis, whereas expression of antisense A20 rendered cells more sensitive to OxLDL. These results suggest that OxLDL not only induces cell death, as has been shown before, but also compromises antiapoptotic protection of activated EC. OxLDL sensitizes EC to apoptotic triggers by interfering with the induction of A20 during the inflammatory response seen in atherosclerotic lesions. This inhibition is based on repression of NF-kappaB activation. The effect may be caused by the OxLDL component LPC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181793     DOI: 10.1681/ASN.V123456

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

1.  Exposure to oxidized low-density lipoprotein reduces activable Ras protein in vascular endothelial cells.

Authors:  Shu-Er Chow; Wing-Keung Chu; Stephen H Shih; Jan-Kan Chen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

2.  Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation.

Authors:  Peter A Keyel; Olga A Tkacheva; Adriana T Larregina; Russell D Salter
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

Review 3.  Biologic effect and molecular regulation of vascular apoptosis in atherosclerosis.

Authors:  Y J Geng
Journal:  Curr Atheroscler Rep       Date:  2001-05       Impact factor: 5.113

4.  Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide.

Authors:  Suwei Wang; Srigiridhar Kotamraju; Eugene Konorev; Shasi Kalivendi; Joy Joseph; Balaraman Kalyanaraman
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

5.  Cryptotanshinone inhibits oxidized LDL-induced adhesion molecule expression via ROS dependent NF-κB pathways.

Authors:  Wenwen Zhao; Chuanhong Wu; Xiuping Chen
Journal:  Cell Adh Migr       Date:  2015-12-08       Impact factor: 3.405

6.  Induced expression of manganese superoxide dismutase by non-toxic concentrations of oxidized low-density lipoprotein (oxLDL) protects against oxLDL-mediated cytotoxicity.

Authors:  Vladimir A Shatrov; Bernhard Brüne
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

7.  Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling.

Authors:  Meng Qin; Yun Luo; Shan Lu; Jing Sun; Ke Yang; Guibo Sun; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.